B7-H1 agonists suppress the PI3K/AKT/mtor pathway by degrading p110γ and independently induce cell death
- Cancer Lett. 2024 Mar 1:584:216615. doi: 10.1016/j.canlet.2024.216615.
- 1. Institute of Immunotherapy, Fujian Medical University, Fuzhou, Fujian, 350102, China. Electronic address: [email protected].
- 2. Institute of Immunotherapy, Fujian Medical University, Fuzhou, Fujian, 350102, China.
- 3. Public Technology Service Center, Fujian Medical University, Fuzhou, Fujian, 350102, China.
- 4. Institute of Immunotherapy, Fujian Medical University, Fuzhou, Fujian, 350102, China; Department of Immunology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, 350102, China.
- 5. Department of Obstetrics, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou 350001, Fujian, China.
The biological role of B7-H1 intrinsic signal is reportedly diverse and controversial, its signal pathway remains unclear. Although B7-H1 blocking antibodies were found to have agonist capacity, their binding features and agonist mechanisms need further investigation. Here, by constructing cell strains with full-length or truncated B7-H1, we found that B7-H1 functioned as a receptor to transmit cell death signal from PD-1 protein or anti-B7-H1s through its cytoplasmic domain. Specific binding to the IgV-like domain of B7-H1 was required for the downstream signal. Upon agonists interaction, B7-H1 regulated the degradation of phosphoinositide 3-kinases (PI3Ks) subunit p110γ, subsequently inhibited the PI3K/Akt/mTOR pathway, and significantly increased Autophagy. Moreover, B7-H1 agonists also suppressed ubiquitylation in B7-H1+cells by reducing ubiquitin-activating enzyme (E1), eventually leading to cell death. Finally, we validated the receptor role of B7-H1 in multiple tumor cells and demonstrated that B7-H1 agonists could suppress tumor progression independent of T cells in vivo. Our findings revealed that B7-H1 agonists functions as a PI3K Inhibitor and may offer new strategies for PI3K targeting therapy.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: PD-1/PD-L1